Considering these conflicting findings, we conducted a pilot systematic review and meta‐analysis to investigate the efficacy of SGLT2 inhibitors in patients following acute MI, by comprehensively analysing data from published randomised controlled trials (RCTs). This evidence concerns the gene SLC5A2 and myocardial infarction.